Brought to you by 
Medivation gets rights to OncoFusion's BET protein inhibitors; rights returned
03 Feb 2023
Executive Summary
Oncology start-up OncoFusion Therapeutics Inc. licensed Medivation Inc. (also developing cancer treatments) exclusive worldwide rights to its preclinical compounds targeting bromodomain and extra-terminal (BET) proteins.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Technologies
- Genomics-Proteomics
-
Drug Discovery Technologies
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Medivation gets rights to OncoFusion's BET protein inhibitors; rights returned
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice